Cargando…
First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation
BACKGROUND: Recent clinical trials reported conflicting results on the reduction of new-onset diabetes using RAS blocking agents. Therefore the role of these agents in preventing diabetes is still not well defined. Ramipril is an ACE inhibitor (ACEi), that has been shown to reduce cardiovascular eve...
Autores principales: | Zidek, Walter, Schrader, Joachim, Lüders, Stephan, Matthaei, Stephan, Hasslacher, Christoph, Hoyer, Joachim, Bramlage, Peter, Sturm, Claus-Dieter, Paar, W Dieter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2529270/ https://www.ncbi.nlm.nih.gov/pubmed/18652658 http://dx.doi.org/10.1186/1475-2840-7-22 |
Ejemplares similares
-
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study
por: Zidek, Walter, et al.
Publicado: (2012) -
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients
por: Kintscher, Ulrich, et al.
Publicado: (2007) -
Ada 2012 rationale: the language, the standard libraries
por: Barnes, John
Publicado: (2013) -
Association of Baseline Adherence to Antihypertensive Medications With Adherence After Shelter-in-Place Guidance for COVID-19 Among US Adults
por: Egan, Brent M., et al.
Publicado: (2022) -
Health football beats them all: subgroup analysis of the 3F (Fit&Fun with Football) study on white-coat hypertension, sustained hypertension, dippers, nondippers, and on pharmacologically un(treated) arterial hypertension
por: Schrader, Bastian, et al.
Publicado: (2023)